Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Friday, May 19, 2017

European Stroke Organisation - ESOC Day 2 18 May 2017


I see nothing here that helps survivors recover better. Nothing on solving all the problems in stroke. I would say this conference was totally fucking useless.  Better results NOT better care you blithering idiots. Do you want to solve problems or just lazily talk about them?
Oops, once again not following Dale Carnegie, 'How to Win Friends and Influence People'.

http://www.alphagalileo.org/ViewItem.aspx?ItemId=175501&CultureCode=en
Collaboration and the Future of Stroke Care Drive Discussion on Day 2 of ESOC 2017
See video interviews and summary slides at:
http://www.esoc2017.com/conference-information/conference-news

The European Stroke Organisation's (ESO) ongoing commitment to collaboration with other stakeholders in stroke prevention, treatment and management was clearly evident in today's congress programme with four sessions on shared focus areas.
ESO and the Stroke Alliance For Europe (SAFE), the region's leading stroke patient organisation, launched the Burden of Stroke Report.
The report defines current incidence and prevalence of stroke in Europe, care provision, and resulting disability and impact on society.
The release of this report lays the foundation for the ESO-SAFE Action Plan for Europe 2018-2030 which aims to guide European policy on stroke care for the next decade.
A joint session between ESO and the World Stroke Organisation provided a 'Global Perspective on Stroke', from the effect of poverty to current approaches aimed at reducing the impact of stroke on a global scale. Jon Barrick, SAFE President and WSO Chair of the World Stroke Campaign Committee, co- chaired the session with WSO President Prof Werner Hacke. "It was clear from the presentations that stroke is related to poverty," said Mr. Barrick. "As such, stroke is not just a health issue but requires economic and government action.
The message to governments from advocacy groups like SAFE and WSO is that their decisions have consequences in health terms." He added that one of the most striking points of the session is that air pollution was ranked 5th on the list of stroke risk factors. "Risk factors 1 to 4 can all be managed by changes in lifestyle or with the assistance of medication," he said. "Poverty and air pollution are, in most cases, beyond the individual's control." The session also highlighted that there is a greater proportion of haemorrhagic stroke compared to ischaemic stroke amongst the poorest people in the poorest regions of the world. "Poverty and air pollution are, in most cases, beyond the individual's control," commented Mr. Barrick. "We need to address these issues at a national and global level."
ESO and the Chinese Stroke Association (CSA) compared the differences in stroke care and research between the different healthcare systems. A number of clinical trials in China have informed practice in recent years, e.g. CHANCE study (Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. The ESO-CSA collaboration aims to build on this already successful partnership.
The ESO EAN ESMINT SAFE collaboration presented their survey of the current provision of stroke care in Europe and what needs to be done in the next decade to meet the challenges ahead. The survey highlighted the need to adopt common standards and ensure better access to stroke treatments across Europe.

No comments:

Post a Comment